ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-B7-H4/MMAE ADC LNCB74

Its studies are mostly in Ovarian Neoplasms, led by LigaChem Biosciences.

Furthest: phase 1, since Jan 8, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LigaChem Biosciences11 open or runningphase 1since Jan 8, 2025Jan 8, 2025Dec 2027phase 1 · NCT06774963

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2025First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT06774963 · 145 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 1 study in Ovarian NeoplasmsNCT06774963

TargetBeta

VTCN1 →read by rule
“An antibody-drug conjugate (ADC) composed of a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the T-cell checkpoint ligand B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) ”NCIt, by rule

Other programs on VTCN1

ProgramCompanyFurthest phaseStudies
mocertatug rezetecanGlaxoSmithKlinephase 311
Anti-B7-H4 Antibody Drug Conjugate BG-C9074ruleBeOne Medicinesphase 32
puxitatug samrotecanAstraZenecaphase 32
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103ruleabl-bio-incphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06774963Ovarian Neoplasms · United States1RecruitingDec 2027145

How it is read

Names in the registry

  • “LNCB74”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.